Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

• Status: Terminated
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to see if a topical beta blocker is effective in preventing the proliferation of infantile hemangioma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alice K. Gong
• Treatments: Maleic acid; Timolol

Criteria

Inclusion Criteria:

• Babies admitted to NICU or seen in follow clinic that have a diagnosis of hemangioma that is verified by Principal Investigator (PI) or Co-Principal Investigators.

Exclusion Criteria:

• Babies with PHACES (Posterior fossa, Hemangioma, Arterial lesions, Cardiac abnormalities, Eye abnormalities) syndrome

• Babies with cardiac conditions that may predispose to heart block

• Babies with persistent hypoglycemia

• Babies on medications that may interact with beta blockers

• Babies who are hemodynamically unstable and are requiring pressors to maintain blood pressure

• Babies who are on systemic corticosteroid therapy